Compare TROX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROX | ARVN |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.2M | 781.0M |
| IPO Year | 2005 | 2018 |
| Metric | TROX | ARVN |
|---|---|---|
| Price | $4.92 | $11.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 23 |
| Target Price | $4.69 | ★ $17.89 |
| AVG Volume (30 Days) | ★ 4.9M | 872.3K |
| Earning Date | 02-11-2026 | 02-10-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,844,000,000.00 | $312,300,000.00 |
| Revenue This Year | N/A | $11.17 |
| Revenue Next Year | $3.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 93.86 |
| 52 Week Low | $2.86 | $5.90 |
| 52 Week High | $10.60 | $20.90 |
| Indicator | TROX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 68.68 | 49.67 |
| Support Level | $4.08 | $11.01 |
| Resistance Level | $4.30 | $12.00 |
| Average True Range (ATR) | 0.21 | 0.54 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 93.86 | 44.09 |
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.